论文部分内容阅读
Lubiprostone是2006年1月经FDA批准上市,用于治疗成人慢性特发性便秘症的新药。该药由Sucampo制药公司研制,并经Sucampo制药公司与北美Takeda公司联合开发在美国上市,商品名Amitiza,为口服胶囊剂。lubiprostone(Amitiza)Lubiprostone作为局部作用的氯离子通道激活剂,能够特异性
Lubiprostone is a new drug marketed by the FDA in January 2006 for the treatment of chronic idiopathic constipation in adults. Developed by Sucampo Pharmaceuticals, the drug is marketed in the United States by Sucampo Pharmaceuticals and North American Takeda under the Amitiza trade name for oral capsules. lubiprostone (Amitiza) Lubiprostone acts as a topical chloride ion channel activator capable of specificity